B of A Securities Downgrades Humana to Underperform, Lowers Price Target to $247
Humana's Star Rating Decline Prompts Hold Rating Amid Financial Uncertainty
Buy Rating Affirmed: Humana's Proactive Strategies to Mitigate Earnings Headwinds
Humana Analyst Ratings
RBC Capital Maintains Humana(HUM.US) With Buy Rating, Maintains Target Price $400
Baird Maintains Humana(HUM.US) With Hold Rating, Maintains Target Price $374
Humana Price Target Cut to $250.00/Share From $400.00 by Leerink Partners
Humana Cut to Market Perform From Outperform by Leerink Partners
J.P. Morgan Weighs in on Humana Stock Following Medicare Star Rating Changes
Stephens Downgrades Humana to Equalweight From Overweight, Cuts Price Target to $250 From $400
Wolfe Research Maintains Humana(HUM.US) With Buy Rating, Cuts Target Price to $342
Cantor Fitzgerald Reiterates Neutral on Humana, Maintains $395 Price Target
Humana Analyst Ratings
Jefferies Maintains Humana(HUM.US) With Buy Rating, Maintains Target Price $419
Wolfe Research Adjusts Price Target on Humana to $342 From $400
Humana Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Humana, Maintains $395 Price Target
Humana Is Maintained at Outperform by RBC Capital
Humana Analyst Ratings
Update: RBC Raises Price Target on Humana to $400 From $385, Maintains Outperform Rating